$14.63
+18%ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Chief Business Officer
Compensation
$559,111
Chief Financial Officer
Compensation
$616,373
Chief Operating Officer
General Counsel & Secretary
President, Chief Executive Officer & Director
Compensation
$1,232,679
During the last 12 months, insiders have sold $1.45M worth of CLPT shares, with no buying activity reported.
0
0.00
26.5K
308.05K
-308K
-$308K
0
0.00
42.9K
670.88K
-671K
-$671K
0
0.00
17.6K
466.12K
-466K
-$466K
0
0.00
0
0.00
+0
+$0
No buying activity
Burnett Joseph
Director, Officer: Ceo And President
$1.14M
Klein Matthew B.
Director
$185K
Richards Timothy T.
Director
$66K
Fallon Lynnette C
Director
$57K
Strong bearish signal with $1.45M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
4 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
CLPT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 10, 2026 | April 10, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 09, 2025 | May 21, 2025 | 2025 | |
DEF 14A DEF 14A 2023 N/A | April 05, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A N/A | April 14, 2023 | April 14, 2023 | ||
DEF 14A DEF 14A 2021 N/A | April 11, 2022 | December 31, 2021 | 2021 | |
DEF 14A DEF 14A 2021 N/A | April 19, 2021 | June 03, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 20, 2020 | June 02, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 16, 2019 | April 16, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 30, 2018 | April 30, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | September 05, 2017 | September 05, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.